- Home
- AFCG vs FLNA Comparison
AFCG vs FLNA Comparison
Compare AFCG & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFCG | FLNA |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.4M | 61.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | AFCG | FLNA |
|---|---|---|
| Price | $3.06 | $1.19 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | 280.8K | ★ 416.3K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $24,563,601.00 | N/A |
| Revenue This Year | $1,334.03 | N/A |
| Revenue Next Year | $17.33 | N/A |
| P/E Ratio | $5.87 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.06 | $1.16 |
| 52 Week High | $5.78 | $2.03 |
Technical Indicators
Market Signals| Indicator | AFCG | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 27.07 |
| Support Level | $2.74 | N/A |
| Resistance Level | $3.42 | $1.80 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 46.78 | 5.89 |
Price Performance
Historical ComparisonAbout AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is an externally managed Maryland corporation that operates as a Business Development Company (BDC). The firm's primary operations involve originating, structuring, underwriting, and managing senior secured loans and other debt securities. Its investment portfolio includes loans to state law-compliant cannabis operators, ancillary cannabis businesses, and middle-market companies in other industries. These loans are typically secured by collateral such as real estate, equipment, cash flows, and license values.
About FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.